Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2020

View Archived Issues

Multistep method wrests causality from GWAS

Loss of neurofibromin enhances ER function and therapy resistance in ER+ breast cancer

Axim Biotechnologies completes preclinical drug studies on SPX-1009

IND application for CS-12192 accepted in China

Intravitreal Eylea approved for neovascular glaucoma

Latuda tablets approved in Japan

Stelara approved for adults with moderate to severe ulcerative colitis in Japan

Phase I data presented for GDC-0214

Novel fungal mouse model of chronic rhinosinusitis

Sanofi receives approval for Soliqua, a combination agent to treat type 2 diabetes, in Japan

Dupixent approved for additional indication of chronic rhinosinusitis with nasal polyp

IL-4 receptor is a therapeutic target in atopic dermatitis

Genentech presents new IRE1 inhibitors

Betta Pharmaceuticals divulges PD-1/PD-L1 and/or PD-L1/CD80 interaction inhibitors

NiKang Therapeutics synthesizes HIF2A inhibitors

Medicenna presents preclinical data on IL-2 Superkine MDNA-19

Velexbru approved in Japan for recurrent or refractory primary central nervous system lymphoma

Japan first in world to approve Viltepso for Duchenne muscular dystrophy

Medshine Discovery identifies new KDM1A inhibitors

Chengdu Kanghong Pharmaceutical patents new analgesics

Japanese approval of Lokelma for hyperkalemia

Scorpion venom could be useful in fetal alcohol spectrum disorders

Phase I data with inzomelid support progression to phase II

Sun Pharma begins healthy volunteer study of SCO-120

LB-1148 improves bowel function after cardiovascular surgery in phase II trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...